Aleix Prat
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 238 publications
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 20, 2026
Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 20, 2026
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Comprehensive Cancer Centre Accreditation: Experience and Achievements of a Head Neck Cancer Unit.
Journal: Acta otorrinolaringologica espanola
Published: February 06, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: January 28, 2026
Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.
Journal: Therapeutic advances in medical oncology
Published: January 27, 2026
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.
Journal: NPJ precision oncology
Published: January 23, 2026
HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort.
Journal: Breast (Edinburgh, Scotland)
Published: January 12, 2026
Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].
Journal: ESMO open
Published: January 06, 2026
Response to the letter to the editor entitled "The precision of a report on precision".
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: December 25, 2025
Last Updated: 09/26/2026